Novel Vaccines Against Multiple Subtypes Of Dengue Virus

Abstract

An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide, such as a consensus dengue prME that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all 4 dengue subtypes.

1 . A nucleic acid construct capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of Dengue virus, comprising:
 an encoding nucleotide sequence that expresses the polypeptide, wherein the polypeptide includes a PRM/E domain from at least two different Dengue virus subtypes,   a promoter that regulates expression of the polypeptide in the mammal and is operably linked to the encoding nucleotide sequence.   
     
     
         2 . The nucleic acid construct of  claim 1 , further comprising an IgE leader sequence operatively linked to an N-terminal end of the coding sequence and operably linked to the promoter. 
     
     
         3 . The nucleic acid construct of  claim 1 , further comprising a polyadenylation sequence attached to the C-terminal end of the coding sequence. 
     
     
         4 . The nucleic acid construct of  claim 1 , wherein the nucleic acid construct is codon optimized. 
     
     
         5 . The nucleic acid construct of  claim 1 , wherein the encoding nucleotide sequence encodes a polypeptide that includes a DIII domain from dengue virus-subtype 1, dengue virus-subtype 2, dengue virus-subtype 3, or dengue virus-subtype 4, or a combination thereof. 
     
     
         6 . The nucleic acid construct of  claim 1 , wherein the encoding nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, nucleotide sequence encoding SEQ ID NO: 2, SEQ ID NO: 3, nucleotide sequence encoding SEQ ID NO: 4, SEQ ID NO: 5, nucleotide sequence encoding SEQ ID NO: 6, SEQ ID NO: 7, and nucleotide sequence encoding SEQ ID NO: 8. 
     
     
         7 . A DNA plasmid vaccine capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising:
 a DNA plasmid capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, the consensus dengue antigen comprising consensus DIII domain of dengue virus-subtype 1, dengue virus-subtype 2, dengue virus-subtype 3, or dengue virus-subtype 4, or a combination thereof, and   a pharmaceutically acceptable excipient;   the DNA plasmid comprising a promoter operably linked to a coding sequence that encodes the consensus dengue antigen.   
     
     
         8 . The DNA plasmid vaccine of  claim 7 , wherein the DNA plasmid further comprises an IgE leader sequence attached to an N-terminal end of the coding sequence and operably linked to the promoter. 
     
     
         9 . The DNA plasmid vaccine of  claim 7 , wherein the DNA plasmid further comprises a polyadenylation sequence attached to the C-terminal end of the coding sequence. 
     
     
         10 . The DNA plasmid vaccine of  claim 7 , wherein the DNA plasmid is codon optimized. 
     
     
         11 . The DNA plasmid vaccine of  claim 7 , wherein the pharmaceutically acceptable excipient is an adjuvant. 
     
     
         12 . The DNA plasmid vaccine of  claim 11 , wherein the adjuvant is selected from the group consisting of: IL-12 and IL-15. 
     
     
         13 . The DNA plasmid vaccine of  claim 7 , wherein the pharmaceutically acceptable excipient is a transfection facilitating agent. 
     
     
         14 . The DNA plasmid vaccine of  claim 13 , wherein the transfection facilitating agent is a polyanion, polycation, or lipid. 
     
     
         15 . The DNA plasmid vaccine of  claim 13 , wherein the transfection facilitating agent is poly-L-glutamate at a concentration less than 6 mg/ml. 
     
     
         16 . The DNA plasmid vaccine of  claim 7 , wherein the DNA plasmid vaccine has a concentration of total DNA plasmid of 1 mg/ml or greater. 
     
     
         17 . The DNA plasmid vaccine of  claim 7 , wherein the DNA plasmid comprises a plurality of unique DNA plasmids, wherein each of the plurality of unique DNA plasmids encodes a polypeptide comprising a PRM/E domain from dengue virus-subtype 1, dengue virus-subtype 2, dengue virus-subtype 3, or dengue virus-subtype 4, or a combination thereof. 
     
     
         18 . The DNA plasmid vaccine of  claim 7 , wherein the encoding nucleotide sequence comprises one or more sequences selected from the group consisting of SEQ ID NO: 1, nucleotide sequence encoding SEQ ID NO: 2, SEQ ID NO: 3, nucleotide sequence encoding SEQ ID NO: 4, SEQ ID NO: 5, nucleotide sequence encoding SEQ ID NO: 6, SEQ ID NO: 7 and nucleotide sequence encoding SEQ ID NO: 8. 
     
     
         19 . The DNA plasmid vaccine of  claim 7 , comprising at least two different DNA plasmids that express a Dengue virus PRM/E domain, the plasmids selected from the group consisting of:
 a DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype 1 PRM/E domain,   a DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype 2 PRM/E domain,   a DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype 3 PRM/E domain, and   a DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype 4 PRM/E domain.   
     
     
         20 . The DNA plasmid vaccine of  claim 7 , comprising:
 the DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype 1 PRM/E domain,   the DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype 2 PRM/E domain,   the DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype 3 PRM/E domain, and   the DNA plasmid comprising a sequence that encodes a consensus dengue virus-subtype 4 PRM/E domain.   
     
     
         21 . The DNA plasmid vaccine of  claim 7 , wherein the consensus dengue virus-subtype 1 PRM/E domain is SEQ ID NO: 1, wherein the consensus dengue virus-subtype 2 PRM/E domain is SEQ ID NO: 3, wherein the consensus dengue virus-subtype 3 PRM/E domain is SEQ ID NO: 5, and wherein the consensus dengue virus-subtype 4 PRM/E domain is SEQ ID NO: 7. 
     
     
         22 .- 24 . (canceled) 
     
     
         25 . The DNA plasmid vaccine of  claim 7 , wherein the mammal is a nonhuman primate. 
     
     
         26 . The DNA plasmid vaccine of  claim 7 , wherein the immune response is selected from the group consisting of a humoral response a cellular response, and a combination thereof. 
     
     
         27 .- 28 . (canceled) 
     
     
         29 . A method of eliciting an immune response against a plurality of subtypes of a virus in a mammal, comprising,
 delivering a DNA plasmid vaccine to tissue of the mammal, the DNA plasmid vaccine comprising a DNA plasmid capable of expressing a plurality of consensus antigens derived from the subtypes of the virus in a cell of the mammal to elicit an immune response in the mammal, the plurality of consensus antigens comprising an antigenic domain from at least two different subtypes of the virus, and   electroporating cells of the tissue with a pulse of energy at a constant current effective to permit entry of the DNA plasmids into the cells.   
     
     
         30 . The method of  claim 29 , wherein the virus comprises west nile virus, human immunodeficiency virus, influenza virus, or dengue virus. 
     
     
         31 . The method of  claim 29 , wherein the delivering step comprises:
 injecting the DNA plasmid vaccine into intradermic, subcutaneous or muscle tissue.   
     
     
         32 . The method of  claim 29 , further comprising:
 presetting a current that is desired to be delivered to the tissue; and   electroporating cells of the tissue with a pulse of energy at a constant current that equals the preset current.   
     
     
         33 . The method of  claim 29 , wherein the electroporating step further comprises:
 measuring the impedance in the electroporated cells;   adjusting energy level of the pulse of energy relative to the measured impedance to maintain a constant current in the electroporated cells;   wherein the measuring and adjusting steps occur within a lifetime of the pulse of energy.   
     
     
         34 . The method of  claim 29 , wherein the electroporating step comprises:
 delivering the pulse of energy to a plurality of electrodes according to a pulse sequence pattern that delivers the pulse of energy in a decentralized pattern.